NCT04110873 - A Phase II, Placebo-controlled Trial Evaluating the Efficacy of Antroquinonol in Patients With Atopic Dermatitis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 27, 2018

Primary Completion Date

June 25, 2019

Study Completion Date

June 25, 2019

Conditions

Atopic Dermatitis

Interventions

DRUG

Antroquinonol Capsule 50mg

patients will receive Antroquinonol 50mg per day (QD) on Day 1 for 12 weeks

DRUG

Antroquinonol Capsule 100mg

patients will receive Antroquinonol 100mg per day (QD) on Day 1 for 12 weeks

DRUG

Placebo oral capsule

patients will receive placebo per day (QD) on Day 1 for 12 weeks

Trial Locations (1)

Chung Shan Medical University Hospital, Taichung